#liver decompensation

People who are living with all three viruses have a greater likelihood of progressing to end-stage liver disease.

A recent Swedish study defined a low-level detectable viral load as between 50 and 999.

In the era of highly effective treatments for both viruses, HIV doesn’t speed the advancement of cirrhosis.

Researchers followed nearly 10,000 people with hepatitis C, some of whom were treated with direct-acting antivirals.

Scientists have firmly established an association between direct-acting antiviral treatment and a lower risk of liver cancer and death.

Indicators of liver health improved at the same rate among those with cirrhosis who were cured of hep C regardless of their HIV status.

Better antiretrovirals have likely mitigated HIV’s effects on the risk of end-stage liver disease and liver cancer in those with hep C.

Highlights from research presented at the 52nd International Liver Congress in Amsterdam

Those coinfected with hepatitis C and HIV who have advanced fibrosis should receive hep C therapy, because of the risk of developing liver dec...

Even a partial response to hepatitis C virus (HCV) therapy confers significant health benefits to people coinfected with both HIV and HCV, tho...